anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mosquito-borne dengue (DENV) and Zika (ZIKV) viruses originated in Old World sylvatic (forest) cycles involving monkeys and canopy-living Aedes mosquitoes. Both viruses spilled over into human transmission and were translocated to the Americas, opening a path for spillback into Neotropical sylvatic cycles. Studies of the trade-offs that shape within-host dynamics and transmission of these viruses are lacking, hampering efforts to predict spillover and spillback. We infected a native, Asian host species (cynomolgus macaque) and a novel, American host species (squirrel monkey) with sylvatic strains of DENV-2 or ZIKV via mosquito bite. We then monitored aspects of viral replication (viremia), innate and adaptive immune response (natural killer (NK) cells and neutralizing antibodies, respectively), and transmission to mosquitoes. In both hosts, ZIKV reached high titers that translated into high transmission to mosquitoes; in contrast DENV-2 replicated to low levels and, unexpectedly, transmission occurred only when serum viremia was below or near the limit of detection. Our data reveal evidence of an immunologically-mediated trade-off between duration and magnitude of virus replication, as higher peak ZIKV titers are associated with shorter durations of viremia, and higher NK cell levels are associated with lower peak ZIKV titers and lower anti-DENV-2 antibody levels. Furthermore, patterns of transmission of each virus from a Neotropical monkey suggest that ZIKV has greater potential than DENV-2 to establish a sylvatic transmission cycle in the Americas.
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly recognised adult-onset multisystem autoinflammatory disease caused by a somatic mutation in the UBA1 gene in myeloid or erythroid precursor cells. This report describes an atypical presentation of recurrent dacryoadenitis associated with VEXAS syndrome and provides a review of the literature. A 68-year-old male presented with three episodes of unilateral alternating dacryoadenitis followed by bilateral involvement over a 4-year period. Each episode of orbital inflammation was characterised by upper lid swelling, oedema and enlarged lacrimal glands. In addition, he experienced intermittent flares of angioedema-like lesions involving the face and extremities, recurrent jaw aches, rash, progressive pulmonary fibrosis, and myelodysplastic syndrome. His inflammatory symptoms lessened with prednisolone but were refractory to methotrexate. Mycophenolate was subsequently trialled with a reasonable clinical response. Genetic testing established the diagnosis of VEXAS syndrome and tofacitinib, a JAK inhibitor, was commenced with resolution of inflammatory symptoms.
This present invention relates generally to the field of chemistry, food industry, cosmetics, and pharmaceutical industry. More specifically, the present invention relates to liposomal biologically active forms and methods of producing thereof. The present invention provides a stable phospholipid emulsion based on dihydroquercetin (DHQ), its compounds and derivatives. The invention further provides a method a quite simple and economic method for the preparation of disclosed emulsion. The disclosed emulsion is characterized by the improved bioavailabilty and selectivity of the effect of active compounds and by the increased stability and prolonged storage terms. The claimed result is achieved using a phospholipid emulsion containing DHQ, its compounds and/or derivatives, at least one membrane-forming phospholipid, at least one zwitter-ion amino acid base, aminoacetic ether, and aqueous ethanol in the following ratio of components (wt %): Dihydroquercetin, 0.01-3; Phospholipid, 0.15-10; Zwitter-ion amino acid base, 0-8; Aminoacetic ether, 0-4; Aqueous ethanol solution (with ethanol concentration within 0.05-20%), 75-98.84.
Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour "loading dose" of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct "dose" for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion.
This systematic review and meta-analysis examined the physiological mechanisms responsible for lower peak exercise leg oxygen uptake (V̇o2) in patients with chronic disease. Studies measuring peak leg V̇o2 (primary outcome) and its physiological determinants during large (cycle) or small muscle mass exercise (single-leg knee extension, SLKE) in patients with chronic disease were included in this meta-analysis. Pooled estimates for each outcome were reported as a weighted mean difference (WMD) between chronic disease and controls. We included 10 studies that measured peak leg V̇o2 in patients with chronic disease (n = 109, mean age: 45 yr; encompassing chronic obstructive pulmonary disease, COPD, heart failure with reduced ejection fraction, HFrEF, or chronic renal failure, RF) and age-matched controls (n = 88). In pooled analysis, peak leg V̇o2 (WMD; -0.23 L/min, 95% CI: -0.32 to -0.13), leg oxygen (O2) delivery (WMD: -0.27 L/min, 95% CI: -0.37 to -0.17), and muscle O2 diffusive conductance (WMD: -5.2 mL/min/mmHg, 95% CI: -7.1 to -3.2) were all significantly lower during cycle and SLKE exercise in chronic disease versus controls. These results highlight that during large and small muscle mass exercise in patients with COPD, HFrEF, or RF, there is no single factor causing peak V̇o2 limitations. Specifically, the lower peak V̇o2 in these pathologies is due to not only the expected impairments in convective O2 delivery but also impairments in muscle oxygen diffusive transport from capillary to mitochondria. Whether impaired muscle O2 transport is caused solely by inactivity or additional muscle pathology remains in question.NEW & NOTEWORTHY Peripheral (skeletal muscle and vasculature) factors contribute significantly to reduced exercise capacity during both large and small muscle mass exercise in chronic diseases such as COPD, HFrEF, or RF and should be important targets of therapy in addition to the primary organs (lungs, heart, and kidneys) affected by disease.
Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
AIMS: Chronic systolic heart failure (CHF) is a major health burden. A relevant number of patients shows asymptomatic left ventricular dysfunction (ALVSD) before symptomatic CHF or becomes asymptomatic after initiating heart failure therapy. Clinical course, prognosis, and response to pharmacological and device-based treatment are largely unknown in these two distinct groups of patients. Current pharmacological and interventional therapies do neither properly address the underlying pathophysiology nor prevent malignant loss of function. New therapeutic paradigms are needed to stop the progression from asymptomatic to symptomatic heart failure. Key questions are what causes progression of clinically asymptomatic New York Heart Association (NYHA) I heart failure to overt heart failure (>NYHA I) in some but not all patients and the underlying reasons for this transition. This requires the identification of disease mechanisms and biomarkers that predict outcome in well-defined cohorts for innovative preclinical and clinical trials.
METHODS AND RESULTS: TransitionCHF is a prospective, multicentre, longitudinal pathophysiological evaluation cohort study in patients with asymptomatic systolic dysfunction NYHA I and left ventricular ejection fraction ≤40%. The cohort comprises both incidental findings and patients who had become asymptomatic after a previous symptomatic event. TransitionCHF has recruited 1000 patients with ALVSD caused by various aetiologies in 20 university heart failure clinics across Germany. Both patients with and without comorbidities at study entry will be recruited. Patients will be systematically investigated and followed up annually over the course of the study. The primary composite endpoint is time to hospitalization for heart failure and cardiovascular death. The secondary endpoints assess time to all-cause mortality, to cardiovascular mortality, to heart failure mortality, to all-cause hospitalization, to heart failure hospitalization, and to recurrent heart failure hospitalizations, as well as time to assist device implantation/transplantation. Additional investigations focusing on biomarkers, comorbidities, gender aspects, nutrition, and functional parameters including quality of life will be performed.
CONCLUSIONS: TransitionCHF will provide a more thorough pathophysiological understanding of the progression of asymptomatic systolic dysfunction into symptomatic heart failure that will help develop therapies tailored to prevent progressive heart failure.
Objectives: Drowning is one of the most common causes of accidental deaths in all age groups. This study aims to compare the sociodemographic data, scene of incident findings, clinical characteristics, and autopsy findings of Turkish and foreign victims of drowning in Antalya, one of the most popular global holiday destinations. Study Design: This study is the most extensive case series of drowning in Turkey. Methods: A retrospective examination was made of 7775 autopsies, of which 692 (8.9%) were identified as drowning cases. Results: Almost half of the cases were elderly males of foreign nationality, with a chronic disease and high alcohol consumption, who were found wearing swimming clothes and had died accidentally, mostly in the sea or swimming pools. The majority of Turkish victims were male children and adolescents, found wearing normal daily clothes, who died from a fall or while performing high-risk activities, such as jumping from height. Most of these cases died at the scene of the incident due to an accident or suicide. Conclusions: Such incidences of deaths in Antalya could be reduced with the implementation of precautions, with adjustments made according to the increased risks and, particularly, the mobility of the older age group. Significantly, chronic disease is an important risk factor in cases of drowning.
Participants in the TIGER (tenodesis-induced-grip exoskeleton robot) group will operate the TIGER system. They will undergo a 30-minute home-based training program twice a day, 5 days a week for 4 weeks.
HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
Pure zirconium dioxide is obtained by calcining an acetatozirconyl halide of empirical formula Zr(OH)4-(a+b)(CH3COO)aXb.H2O, wherein X is chlorine or bromine, a is 1.30 to 1.50 and b is 0.4 to 0.7, at 800 DEG  C. in an oxidizing atmosphere.ALSO:The invention comprises acetatozirconyl halides of the empirical formula: Zr(OH)4-(a + b) (CH3COO)aXb.H 2O, wherein X is chlorine or bromine, a is 1.30 to 1.50 and h is 0.4 to 0.7. They are prepared by heating zirconyl ions, acetate ions, and chloride or bromide ions in the presence of acetic acid and water to form a permanent precipitate; the water being supplied as water of crystallisation, free water or dilute acetic acid or by a combination of these means. The compounds of the invention can be used to precipitate pigments and toners from solutions of acid dyes (see Divisions C3 and C4) in the cosmetic and pharmaceutical fields (see Division A5) and as a source of pure zirconium dioxide (see Division C1).ALSO:A printing ink contains a zirconium-containing toner formed by reacting an acid dye with an acetatozirconyl halide of empirical formula: Zr4-(a+b) (CH3COO)aXb. H2O, wherein X is chlorine or bromine, a is 1.30 to 1.50 and b is 0.4 to 0.7 (see Division C4).  In Example 8 an ink is formed by grinding the reaction product of orange II dye and an acetatozirconyl halide with blanc fixe, ethyl cellulose, oil-soluble phenol-formaldehyde resin, dibutyl phthalate, octyl phenol, butanol and ethylene glycol monoethyl ether in a ball mill.ALSO:The invention comprises zirconium containing pigments and toners comprising the reaction product of an acid dye and an acetatozirconyl halide of empirical formula Zr(OH)(4-(a+b)(CH3COO)aXb.H2O wherein X is chlorine or bromine, a is 1.30 to 1.50 and b is 0.4 to 0.7.  In Example 7 an aqueous solution of an acetatozirconyl halide is added to an aqueous solution of Orange II dye at 95 DEG  C. and pH 2.5 with stirring over a period of 15 minutes.  The slurry formed is cooled to 50 DEG  C., filtered and the precipitate washed with dilute HCl prior to drying at 55 DEG  C. to yield a bright orange pigment of molar Zr:dye ratio of 2.5:1 and 30.8% acetate content. Other dyes mentioned are erioglaucine and Fast Light Yellow 3G.ALSO:Cosmetic and pharmaceutical compositions comprise novel acetatozirconyl halides of empirical formula <FORM:0965788/A5-A6/1> wherein X is chlorine or bromine, a is 1.30 to 1.50 and b is 0.4 to 0.7.
Application of total monoterpene glycoside of radix Paeoniae Rubra and analysis method of active ingredient in total monoterpene glycoside of radix Paeoniae Rubra are provided. The invention establishes 11 batches of red paeony total monoterpene glycoside fingerprint spectra of different producing areas by adopting UPLC-MS/MS technology for the first time, and lays a foundation for revealing the effective component group of the red paeony total monoterpene glycoside. The invention totally determines 5 compounds with muscle increasing effect mainly comprising red paeony total monoterpene glycoside, wherein 4 monoterpene glycoside compounds have one isomer belonging to benzoyl paeoniflorin. Use of total monoterpene glycoside of radix Paeoniae Rubra in preparing animal feed or medicine for increasing muscle is provided. The invention establishes a related model of the fingerprint spectrum-drug effect of the total monoterpene glycoside of red paeony root, establishes a quality evaluation standard of the muscle increasing effect based on the fingerprint spectrum of the effective part of the total monoterpene glycoside of red paeony root, and provides a new thought for screening active ingredients of other pharmacological effects of red paeony root. The invention lays a theoretical foundation for the development of muscle-increasing food for body-building people and provides new resources for the development of animal feed additives for animal husbandry.
The preparation of technetium-99m with 6-fluoroquinolones can be a diagnostic imaging agent aiming at the differential diagnosis between infection and sterile inflammation.The present invention relates to the preparation of the standardized technetium-99m cold kit through which the short, simple and safe preparation of radiopharmaceuticals in a single step will be possible by the simple reconstitution of the cold kit's content with injectable Sodium Pertechnetate-99mTc solution.The cold kit contains all the necessary ingredients for this purpose in a stable in vitro formulation. The preparation method is particularly easy-to-use, effective and pharmaceutically appropriate, it allows though the storing of the standardized kits for a sufficient period of time. The content of the kits for the preparation of the radiopharmaceuticals has the form of lyophilized dry powder. It has to be sterile and pyrogen free. The preparation method of the cold kit includes the mixing of the necessary ingredients under aseptic conditions. 1 mg 6-fluoroquinolone, 0.3 mg stannous chloride (SnCl2) and some quantity of an antioxidant (ascorbic acid) are contained per vial. The final solution is lyophilized and the sealing of the vials under vacuum follows. The standardized kit is kept in the refrigerator (2-8 C). The reconstitution/ dissolution of the cold kit is carried out only by the addition of injectable Sodium Pertechnetate-99mTc solution (radioactive 99mTc-technetium labeling). The radioactive solution can be administrated to patients up to 5 hours after the labeling according to the principles of protection against radiation.
A plurality of oligonucleotides are caused to bind specifically to target nucleic acid which is predictive of a disease state or a biological condition within cells containing the target nucleic acid. The respective oligonucleotides, which may be functionilized or may be present in the form of oligonucleotide analogs, carry with them a plurality of synthons. Such synthons, which may be identiphores, toxiphores, or other precursors to biologically effective molecules, interact when specific binding of the respective oligonucleotides occurs at sites adjacent to each other on the target nucleic acid. The resulting interaction gives rise to the synthesis, generation or release of highly active biological molecules in situ in the cell in which the specific binding takes place. This permits the use of extraordinarily toxic molecules for use in killing cells containing the target nucleic acids. Imaging and other uses are also provided by the present invention.
The present invention provides an isolated polypeptide, any one selected from the group consisting of: a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO. 3; or a fragment containing at least SSTSSSKIMSQSQ of the amino acid sequence shown in SEQ ID NO. 3. The invention also provides an isolated polynucleotide having a sequence selected from the group consisting of: a coding sequence for the above polypeptide; or a complement of the coding sequence described above. The invention also provides application of the polypeptide in preparing a medicament for specifically inhibiting Mre11K673 lactogenesis. The invention also provides application of the polypeptide in preparing a medicament for promoting cancer cells to be sensitive to chemotherapy. The invention also provides the use of the lactate modified Mre11K673 in the screening of a medicament for the treatment of cancer, the medicament being a medicament which specifically inhibits the lactate of Mre11K 673. The combination of the polypeptide and the chemotherapeutic agent of the invention significantly promotes the chemotherapy-mediated killing of cancer cells in vitro and in vivo.
FIELD: medicine, veterinary. SUBSTANCE: method involves grinding of testis of cattle and extraction by solvent followed by separation of desired product as solution. Then purification and drying are carried out. 0.85-0.9 solution of sodium chloride is used as said solvent. Extraction is carried out within 5-60 min at pH 5.0-7.0 and 5-50 C, weight ratio of testis and extract solution being 1: 4-2. Desired product is prepared as solution by sustaining or by filtration of extract, purification being carried out by ultrafiltration through membrane material which passes compounds with molecular weight less 15000-30000 dal. EFFECT: improves efficiency of the method. 2 cl
Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
ETHNOPHARMACOLOGICAL RELEVANCE: Radix scutellariae (the root of Scutellaria baicalensis Georgi) is a traditional Chinese medicine (TCM) used to treat a wide range of inflammation-related diseases, such as obesity, diabetes, diabetic kidney disease, and COVID-19-associated inflammatory states in the lung and kidney. Baicalin is the major anti-inflammatory component of Radix scutellariae and has shown the potential to inhibit inflammation in metabolic disorders. In this study, we explored the ability and underlying mechanisms of baicalin to modulate the macrophage to mitigate insulin resistance in obesity.
MATERIALS AND METHODS: Obese mice were administered baicalin (50 mg/kg/day) intraperitoneally for 3 weeks. RAW264.7 and BMDM cells were stimulated with LPS and treated with baicalin for 24 h, while 3T3-L1 and primary white adipocytes were treated with the supernatants from baicalin-treated RAW264.7 cells for 24 h.
RESULTS: The results showed that baicalin significantly improved glucose and insulin tolerance as well as decreased fat and adipose tissue macrophage levels in obese mice. Besides, baicalin significantly reduced serum and adipose tissue IL-1β, TNF-α and IL-6 levels in obese mice, as well as suppressed LPS-induced IL-1β, TNF-α and IL-6 expression and release in macrophages. Furthermore, treatment with the supernatant from baicalin-treated RAW264.7 cells increased the levels of PGC-1α, SIRT1, p-IRS-1 and p-AKT in adipocytes. Moreover, baicalin treatment dramatically downregulated macrophage p-p38, p-JNK, and Ac-p65Lys310 levels while increasing SIRT1 both in vivo and in vitro. Importantly, JNK inhibitor SP600125 blocked most of the effects of baicalin on SIRT1, Ac-p65Lys310 and pro-inflammatory factors in macrophages.
CONCLUSION: Therefore, these results demonstrated for the first time that baicalin exerts its anti-inflammatory effects in obese adipose tissue macrophages mainly through suppressing JNK/SIRT1/p65 signaling. These findings amplified the mechanisms of baicalin and its potential to attenuate insulin resistance.
OBJECTIVES: Criteria for antiviral treatment initiation in Thailand were complex and difficult to implement. This study determined the cost-effectiveness of 2 simplified antiviral treatment initiation criteria among patients with chronic hepatitis B in Thailand.
METHODS: A hybrid model of the decision tree and Markov model was developed. Two simplified antiviral treatment initiation criteria were the expanded criteria, treating patients with hepatitis B surface antigen positive and viral load (hepatitis B virus deoxyribonucleic acid) >2000 IU/mL or cirrhosis by tenofovir alafenamide (TAF), and the test-and-treat criteria, treating patients with hepatitis B surface antigen positive and viral load >10 IU/mL or cirrhosis by TAF. PubMed was searched from its inception to July 2023 to identify input parameters. Best supportive care was chosen for patients who were ineligible for TAF. Incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) was calculated.
RESULTS: The expanded criteria and the test-and-treat could reduce the occurrence of patients progressing to hepatocellular carcinoma. In particular, both criteria could reduce 4846 new cases of hepatocellular carcinoma per 100 000 patients. The incremental cost-effectiveness ratios for the expanded criteria and the test-and-treat criteria were 24 838 Thai baht (THB)/QALY and 163 060 THB/QALY, respectively.
CONCLUSIONS: At the current willingness to pay of 160 000 THB/QALY, the expanded criteria were cost-effective, but the test-and-treat criteria were not cost-effective to be the simplified antiviral treatment initiation criteria for patients with chronic hepatitis B in Thailand.
Compounds, pharmaceutical compositions and methods for treating microbial infections are provided. The compounds, when co-administered with one or more antimicrobial agents, can enhance the therapeutic effect of the one or more antimicrobial agents. The compounds have antiviral properties. The present application provides pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier. The pharmaceutical composition may further comprise at least one antibiotic, such as gentamicin, amikacin, kanamycin, neomycin, spectinomycin, neotoxamine, or any combination thereof. The compounds and compositions are useful for treating or preventing microbial infections.